Physician profile
Debra B Paschal
NPI 1831149319
$8,606.84
in general payments reported to CMS, 2019-2025
22 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,109 · 2022: $1,311 · 2023: $2,301 · 2024: $2,269 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,934 · Education: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,934.16 |
| Education | $252.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,994.57 | 2021-2025 | |
| Genzyme Corporation | $916.90 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $829.48 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $686.05 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $681.04 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $666.74 | 2021-2024 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $630.52 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $513.71 | 2021-2025 | Ilumya |
| Amgen INC. | $344.82 | 2021-2025 | Otezla, Otezla, Enbrel |
| Leo Pharma INC. | $342.11 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $335.03 | 2021-2025 | Bimzelx |
| Pfizer INC. | $206.71 | 2021-2025 | |
| Incyte Corporation | $161.17 | 2022-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $95.40 | 2023-2024 | Zoryve |
| Almirall LLC | $39.14 | 2024 | Seysara |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $38.85 | 2023-2024 | Vtama |
| Organon LLC | $35.00 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $25.85 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.60 | 2024 | Spevigo |
| Teleflex LLC | $16.21 | 2025 | D-Stat |
| Dermira, INC. | $15.47 | 2021 | |
| Linus Health, INC. | $14.47 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Paschal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.